In patients undergoing high dose sequential chemotherapy (HDS) for breast cancer (BC),(1) allogeneic platelet transfusions can be avoided by using cryopreserved autologous platelets.(2) Nevertheless, half of these patients develop a mild anemia before myeloblation, requiring eventually blood transfusion. In this cohort of patients, we evaluated the efficacy of recombinant human erythropoietin (EPO)(3,4) in preventing the development of anemia, and therefore any allogeneic transfusion requirement.
Transfusion requirement can be abolished by epoietin-alpha and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support
Zambelli A;
2000-01-01
Abstract
In patients undergoing high dose sequential chemotherapy (HDS) for breast cancer (BC),(1) allogeneic platelet transfusions can be avoided by using cryopreserved autologous platelets.(2) Nevertheless, half of these patients develop a mild anemia before myeloblation, requiring eventually blood transfusion. In this cohort of patients, we evaluated the efficacy of recombinant human erythropoietin (EPO)(3,4) in preventing the development of anemia, and therefore any allogeneic transfusion requirement.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
